Human Immunodeficiency Virus 1 (HIV-1) PhenoSense Entry® (Monogram® Fuzeon Resistance)
Also known as: Fuzeon® Resistance, PhenoSense Entry®
Use
Determines phenotypic susceptibility to enfuvirtide (Fuzeon®) and assesses likely effectiveness before enfuvirtide is added to a patient's regimen or before changing a regimen that includes enfuvirtide
Special Instructions
To avoid delays in turnaround time, it is recommended that separate frozen plasma specimens be submitted for each test requested if multiple tests are to be performed on frozen samples. Proper specimen handling and processing, such as centrifugation and freezing, are critical to ensure valid results and minimize the risk of test rejection due to improper preparation.
Limitations
This procedure is designed for patients with documented HIV-1 infection and requires a minimum viral load of 1000 copies/mL for accurate testing. The test may not be suitable for patients with viral loads below this threshold, and results may not be representative in cases where the viral load is insufficient for amplification and culture.
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 51969-4
- 82719-6
- 77202-0
Result Turnaround Time
16-26 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL
Minimum Volume
Not provided
Container
Lavender-top (EDTA) or plasma preparation tube (PPT™).
Collection Instructions
Collect specimen in two lavender-top (EDTA) tubes or two PPT™ tubes. Do not use green-top (heparin) tubes. Centrifuge specimen within six hours of collection. Transfer plasma to one or more polypropylene screw-capped tube(s) and freeze. Ship specimen frozen.
Storage Instructions
Freeze
Causes for Rejection
PPT™ not centrifuged; insufficient volume; heparinized plasma; nonfrozen specimens